Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 5/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | SNRNP200 | O75643 | 4/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4041281 | 0.91 | CTSK (0.40) | CTSKCTSLCTSSRENDPP4 | |
| SCHEMBL4042637 | 0.91 | CTSK (0.43) | CTSKCTSLCTSSRENDPP4 | |
| SCHEMBL4040993 | 0.90 | CTSK (0.43) | CTSKCTSLCTSSDPP4DPP9 | |
| SCHEMBL4043803 | 0.90 | CTSK (0.42) | CTSKCTSLCTSSDPP4DPP9 | |
| SCHEMBL4041501 | 0.88 | CTSS (0.42) | CTSKCTSLCTSSREN | |
| SCHEMBL4040009 | 0.87 | CTSK (0.42) | CTSKCTSLCTSSPOLBL3MBTL1 | |
| SCHEMBL4041553 | 0.87 | CTSK (0.41) | CTSKCTSLCTSSDPP4DPP9 | |
| SCHEMBL4043246 | 0.87 | POLB (0.36) | CTSKCTSLCTSSPOLBREN | |
| SCHEMBL4042730 | 0.85 | CTSK (0.40) | CTSKCTSLCTSSDPP4DPP9 | |
| SCHEMBL4042797 | 0.84 | CTSK (0.45) | CTSKCTSLCTSSPOLBREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2132193-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | Boehringer Ingelheim International GmbH (DE) | 2009-12-16 | — | — | EP | claimed |
| EP-2051975-A2 | SUBSTITUTED PROLINAMIDES, PRODUCTION THEREOF AND THEIR USE AS DRUGS | Boehringer Ingelheim International GmbH (DE) | 2009-04-29 | — | — | EP | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| EP-1987021-A1 | SUBSTITUTED PROLINAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-05 | — | — | EP | claimed |
| WO-2008116881-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-02 | — | — | WO | claimed |
| EP-1910345-A1 | SUBSTITUTED AMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Boehringer Ingelheim International GmbH (DE) | 2008-04-16 | — | — | EP | claimed |
| EP-1858890-A1 | NOVEL ANTITHROMBOTIC SUBSTITUTED PYRROLIDINONES, THE PRODUCTION AND USE THEREOF IN THE FORM OF MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-11-28 | — | — | EP | claimed |
| WO-2007131982-A2 | SUBSTITUTED PROLINAMIDES, PRODUCTION THEREOF AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-22 | — | — | WO | claimed |
| EP-1836198-A1 | SUBSTITUTED PYRROLIDINONES HAVING AN ANTITHROMBOTIC EFFECT, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2007-09-26 | — | — | EP | claimed |
| WO-2007093595-A1 | SUBSTITUTED PROLINAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-23 | — | — | WO | claimed |
| EP-1797080-A1 | NOVEL SUBSTITUTED THIOPHENCARBOXYLIC ACID AMIDES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2007-06-20 | — | — | EP | claimed |
| WO-2007009963-A1 | SUBSTITUTED AMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-25 | — | — | WO | claimed |
| WO-2006089909-A1 | NOVEL ANTITHROMBOTIC SUBSTITUTED PYRROLIDINONES, THE PRODUCTION AND USE THEREOF IN THE FORM OF MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-31 | — | — | WO | claimed |
| WO-2006069946-A1 | SUBSTITUTED PYRROLIDINONES HAVING AN ANTITHROMBOTIC EFFECT, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-06 | — | — | WO | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| WO-2006034822-A1 | NOVEL SUBSTITUTED THIOPHENCARBOXYLIC ACID AMIDES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-06 | — | — | WO | claimed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | claimed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| EP-2132193-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | Boehringer Ingelheim International GmbH (DE) | 2009-12-16 | — | — | EP | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885CTSL 57/4885CTSS 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.